Ziyi Jia

The paper identifies acylaminooxadiazole derivatives that kill mycobacteria by inhibiting trans-translation and disrupting iron homeostasis.

This study shows that MHC II and CD4 T cell help are essential for pyrazinamide's antitubercular efficacy, revealing a host-mediated mechanism for its in vivo activity.

The paper develops an orally effective biotin inhibitor, C48, against Mycobacterium tuberculosis, demonstrating in vivo efficacy in a low-biotin mouse model.

This study identifies a dual mechanism of action for morphazinamide, a more potent pyrazinamide analog, showing it kills Mycobacterium tuberculosis through coenzyme A disruption and aldehyde release, which also bypasses resistance.

The paper shows that MBX-4132, a trans-translation inhibitor, kills Mycobacterium tuberculosis and non-tuberculous mycobacteria, with zinc enhancing its activity and iron reducing it.

This study identifies novel anti-TB pro-drugs based on α-aminooxyacetic acid that are effective against M. tuberculosis and show low cytotoxicity.